Posted by Michael Wonder on 21 Aug 2023
Innovent announces the NMPA approval of Sintbilo (tafolecimab injection) for the treatment of adult patients with primary hypercholesterolaemia and mixed dyslipidaemia
17 August 2023 - Innovent Biologics announces that China's National Medical Products Administration has approved Sintbilo (tafolecimab injection, anti-PCSK9 monoclonal antibody) for the treatment of adult patients with primary hypercholesterolaemia (including heterozygous familial and non-familial hypercholesterolaemia) and mixed dyslipidaemia.
As the first domestic PCSK9 inhibitor approved in China, Sintbilo (tafolecimab injection) is Innovent's first drug entering the cardiovascular field, as well as the Company's tenth product in its commercial portfolio.
